Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis

Journal of Psychopharmacology
Patricia GassóPEPs GROUP

Abstract

Hyperprolactinemia is a common side-effect of antipsychotics (APs), which may trigger serious secondary problems and compromise the adherence to treatment which is crucial for prognosis, especially in patients presenting with a first-episode of psychosis (FEP). We evaluated, in some cases for the first time, the effect of polymorphisms in multiple candidate genes on serum prolactin (PRL) levels in an AP-treated FEP cohort recruited in the multicenter PEPs study (Phenotype - genotype and environmental interaction; Application of a predictive model in first psychotic episodes). PRL concentration was measured in serum from 222 patients. A total of 167 polymorphisms were selected in 23 genes. Genetic association analysis was performed in the whole sample and also in homogenous subgroups of patients treated with APs with a high (N = 101) or low risk (N = 95) of increasing PRL release, which showed significant differences in their PRL levels. After Bonferroni correction, polymorphisms in NTRK2, DRD2 and ACE genes were associated with PRL concentration. Our results give more support to the impact of DRD2, but also of other genes related to dopamine availability such as ACE. Moreover, this study provides the first evidence for the invo...Continue Reading

References

Sep 1, 1992·Clinical and Experimental Pharmacology & Physiology·A KuruvillaA S Kanagasabapathy
Mar 1, 1997·Journal of Neurochemistry·T A JenkinsS Y Chai
Oct 4, 2000·Physiological Reviews·M E FreemanG Nagy
Mar 5, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ana B F Emiliano, Julie L Fudge
Aug 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Ross McD YoungErnest P Noble
Nov 24, 2004·The Journal of Clinical Psychiatry·Julie MontgomeryRichard C Josiassen
Jun 30, 2005·Journal of Psychiatric Practice·Uriel Halbreich, Linda S Kahn
Aug 16, 2008·Journal of Psychopharmacology·Peter Fitzgerald, Timothy G Dinan
Apr 3, 2009·Pharmacogenetics and Genomics·Chadi A CalargeJanet A Schlechte
Apr 3, 2010·The American Journal of Psychiatry·David M GardnerRoss J Baldessarini
Aug 27, 2011·Journal of Clinical Psychopharmacology·Rosario López-RodríguezFrancisco Abad-Santos
Sep 13, 2012·The Journal of Clinical Psychiatry·John P HoustonBonnie A Fijal
Dec 5, 2012·Revista de psiquiatrí́a y salud mental·Miquel BernardoUNKNOWN PEPs Group
Apr 6, 2013·Human Psychopharmacology·Teresa CabaleiroFrancisco Abad-Santos
Jan 31, 2014·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Edith ArnoldCarmen Clapp
May 7, 2014·Schizophrenia Research and Treatment·Ravi Philip Rajkumar
Jul 16, 2014·International Clinical Psychopharmacology·Teresa CabaleiroFrancisco Abad-Santos
May 6, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Isabella PacchiarottiEduard Vieta
Dec 20, 2015·Journal of Child and Adolescent Psychopharmacology·Amilton dos Santos JúniorPaulo Dalgalarrondo
Mar 2, 2016·Revista de psiquiatrí́a y salud mental·Ángel L MontejoEduard Vieta
Apr 14, 2016·Schizophrenia Research·Leticia González-BlancoBrian Kirkpatrick

❮ Previous
Next ❯

Citations

Sep 15, 2019·Basic & Clinical Pharmacology & Toxicology·Dora KollerFrancisco Abad-Santos

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

Quanto
Haploview
SPSS statistics

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2022 Meta ULC. All rights reserved